Liu Hai-Ting, Zou Yong-Xin, Zhu Wen-Jie, Zhang Guo-Hao, Ma Ran-Ran, Guo Xiang-Yu, Gao Peng
Key Laboratory for Experimental Teratology of the Ministry of Education and Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China.
Department of Pathology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China.
Cell Death Differ. 2022 Mar;29(3):627-641. doi: 10.1038/s41418-021-00879-9. Epub 2021 Oct 4.
Long noncoding RNAs (lncRNAs) are dysregulated in different cancer types, and thus have emerged as important regulators of the initiation and progression of human cancers. However, the biological functions and the underlying mechanisms responsible for their functions in gastric cancer (GC) remain poorly understood. Here, by lncRNA microarray, we identified 1414 differentially expressed lncRNAs, among which THAP7-AS1 was significantly upregulated in GC tissues compared with non-tumorous gastric tissues. High expression of THAP7-AS1 was correlated with positive lymph node metastasis and poorer prognosis. SP1, a transcription factor, could bind directly to the THAP7-AS1 promoter region and activate its transcription. Moreover, the mA modification of THAP7-AS1 by METTL3 enhanced its expression depending on the "reader" protein IGF2BP1-dependent pathway. THAP7-AS1 promoted GC cell progression. Mechanistically, THAP7-AS1 interacted with the 1-50 Amino Acid Region (nuclear localization signal) of CUL4B through its 1-442 nt Sequence, and it promoted interaction between nuclear localization signal (NLS) and importin α1, and improved the CUL4B protein entry into the nucleus, repressing miR-22-3p and miR-320a expression by CUL4B-catalyzed H2AK119ub1 and the EZH2-mediated H3K27me3, subsequently activating PI3K/AKT signaling pathway to promote GC progression. Moreover, LV-sh-THAP7-AS1 treatment could suppress GC growth, invasion and metastasis, indicating that THAP7-AS1 may act as a promising molecular target for GC therapies. Taken together, our results show that THAP7-AS1, transcriptionally activated by SP1 and then modified by METTL3-mediated m6A, exerts oncogenic functions, by promoting interaction between NLS and importin α1 and then improving the CUL4B protein entry into the nucleus to repress the transcription of miR-22-3p and miR-320a.
长链非编码RNA(lncRNAs)在不同癌症类型中表达失调,因此已成为人类癌症发生和发展的重要调节因子。然而,其在胃癌(GC)中的生物学功能及其功能的潜在机制仍知之甚少。在这里,通过lncRNA芯片,我们鉴定出1414个差异表达的lncRNAs,其中THAP7-AS1在GC组织中与非肿瘤胃组织相比显著上调。THAP7-AS1的高表达与阳性淋巴结转移和较差的预后相关。转录因子SP1可以直接结合到THAP7-AS1启动子区域并激活其转录。此外,METTL3对THAP7-AS1的m⁶A修饰通过“读取器”蛋白IGF2BP1依赖的途径增强了其表达。THAP7-AS1促进GC细胞进展。机制上,THAP7-AS1通过其1-442 nt序列与CUL4B的1-50氨基酸区域(核定位信号)相互作用,促进核定位信号(NLS)与输入蛋白α1之间的相互作用,并促进CUL4B蛋白进入细胞核,通过CUL4B催化的H2AK119ub1和EZH2介导的H3K27me3抑制miR-22-3p和miR-320a表达,随后激活PI3K/AKT信号通路以促进GC进展。此外,LV-sh-THAP7-AS1处理可抑制GC的生长、侵袭和转移,表明THAP7-AS1可能是GC治疗的一个有前景的分子靶点。综上所述,我们的结果表明,由SP1转录激活并随后由METTL3介导的m⁶A修饰的THAP7-AS1通过促进NLS与输入蛋白α1之间的相互作用,进而促进CUL4B蛋白进入细胞核以抑制miR-22-3p和miR-320a的转录,发挥致癌功能。